Meningioma regression following discontinuation of depot medroxyprogesterone acetate.
Neurosurg FocusSep 1, 2026
Alan Gordillo, Pranav Kumar, Nikita Gonugunta et al.
✦ AI-curated · Sources linked
Case in brief
Three patients with meningioma who were under active surveillance experienced tumor regression after discontinuing depot medroxyprogesterone acetate (dMPA). Notably, one patient showed a nearly 39% reduction in tumor burden over 45 months, while another exhibited an 80% decrease over 68 months. The third patient had a 6% reduction, with near-complete resolution of one tumor within 14 months of stopping dMPA.
Diagnostic / clinical pearl
Clinicians should consider the potential for tumor regression in meningioma patients following the cessation of depot medroxyprogesterone acetate, as evidenced by significant reductions in tumor burden in this case series.